For patient information on bamlanivimab alone, click here.
Emergency Use Authorization (EUA) for the Treatment of COVID-19
bamlanivimab and etesevimab
A neutralizing antibody treatment
bamlanivimab 700 mg and etesevimab 1400 mg injection
Important facts about bamlanivimab and etesevimab
Bamlanivimab and etesevimab are investigational medicines used to treat mild to moderate symptoms of COVID-19 in adults and adolescents (12 years of age or older who weigh at least 88 pounds [40 kg]), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
- Bamlanivimab and etesevimab have not been approved, but have been authorized for emergency use by the FDA
- Bamlanivimab and etesevimab are authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab and etesevimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
We are working with the federal government to appropriately plan and allocate supply of bamlanivimab with etesevimab together and plan to communicate more information about the availability of supply in the coming days and weeks.
In the meantime, Lilly will continue to supply bamlanivimab alone under the emergency use authorization. You should discuss with your healthcare provider first if an antibody treatment is right for you.